BriaCell's Bria-OTS+ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BriaCell's Bria-OTS+ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

  • Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell's Bria-OTS+ platform
  • Bria-OTS+, a novel personalized, off-the-shelf, semi-allogeneic cellular immunotherapy may address urgent unmet medical needs for patients with cancer
  • This study was conducted in collaboration with the NCI

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the publication of the mechanism of action of its next generation personalized off-the-shelf immunotherapy. This research conducted in collaboration with the National Cancer Institute (NCI), the US federal government's principal agency for cancer research and training, has been published at JCI Insight, a highly rated peer-reviewed journal dedicated to advancing biomedical research from preclinical discovery through to clinical development.

Publication Title: Enhancing dendritic cell cancer vaccine by allogeneic MHC class II expression and Treg depletion (our reference 189024-INS-RG-RV-4)

"These findings help us better understand the anti-tumor effects of Bria-OTS+ in cancer patients," stated Jay A. Berzofsky, MD, PhD, Senior Investigator of NCI and coauthor of the publication. "The study demonstrated that semi-allogeneic dendritic-cell vaccines recruit alloreactive CD4⁺ T-cell help through mismatched MHC class II molecules, which in turn strengthens antigen-specific CD8⁺ T-cell responses against tumors."

"This publication validates the core design principle behind Bria-OTS+: partial HLA matching enables effective tumor-antigen presentation, while planned HLA mismatching drives robust CD4⁺ helper responses," noted Miguel Lopez-Lago, PhD, BriaCell's Chief Scientific Officer. "These findings are directly aligned with BriaCell's pipeline of allogeneic immunotherapies, reinforcing our strategy to deliver powerful and scalable treatments for cancer patients."

"These data are consistent with the encouraging clinical results we recently reported in our Phase 1/2a study in metastatic breast cancer and provide important insights into the mechanism of action of our cellular immunotherapy platform technology," added Dr. William V. Williams, BriaCell's President and CEO.

For the copy of the publication, please visit: https://briacell.com/scientific-publications/ .

About Bria-OTS

Bria-OTS is a next generation, off-the-shelf personalized immunotherapy based on BriaCell's lead candidate Bria-IMT currently being evaluated in a Phase 1/2a study (ClinicalTrials.gov identifier: NCT06471673 ) in patients with metastatic recurrent breast cancer. The trial includes both monotherapy dose escalation and check point inhibition combination dose expansion cohorts. The Company recently progressed into the dose expansion phase.

About briacell therapeutics corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/ .

Safe Harbor

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include statements regarding Bria-OTS+'s potential to address urgent unmet medical needs for patients with cancer; and BriaCell delivering powerful and scalable treatments for cancer patients. These statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date and briacell therapeutics corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com

Investor Relations Contact:
investors@briacell.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

BCT:CA
The Conversation (0)
TSX:BCT

BriaCell

Developing Personalized Off-The-Shelf Immunotherapy Treatments for Cancer Patients

BriaCell Partners with New York Cancer & Blood Specialists  for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

BriaCell Partners with New York Cancer & Blood Specialists for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a partnership with New York Cancer & Blood Specialists (NYCBS), a group of... Keep Reading...
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or physician's choice therapy (1:1) Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT™ The study's primary... Keep Reading...
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

Median overall survival of 13.5 months in BriaCell's advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature) 21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's combination regimen No... Keep Reading...
BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

briacell therapeutics corp. closes Arrangement effecting the distribution described in the plan of arrangement. briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology company that develops novel immunotherapies to transform... Keep Reading...
BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT in High-Risk Early-Stage Triple Negative Breast Cancer

BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT in High-Risk Early-Stage Triple Negative Breast Cancer

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has accepted a letter of intent from Dr. Massimo Cristofanilli, Director of Breast... Keep Reading...
FY25 Preliminary Results Summary and Company Update

FY25 Preliminary Results Summary and Company Update

Cardiex Limited (CDX:AU) has announced FY25 Preliminary Results Summary and Company UpdateDownload the PDF here. Keep Reading...
Appendix 4E

Appendix 4E

Cardiex Limited (CDX:AU) has announced Appendix 4EDownload the PDF here. Keep Reading...
Appendix 4E and Preliminary Final Report

Appendix 4E and Preliminary Final Report

Radiopharm Theranostics (RAD:AU) has announced Appendix 4E and Preliminary Final ReportDownload the PDF here. Keep Reading...
Appendix 4E and Annual Report

Appendix 4E and Annual Report

Invion Limited (IVX:AU) has announced Appendix 4E and Annual ReportDownload the PDF here. Keep Reading...
Orphan Drug Designation Granted by U.S. FDA for Anal Cancer

Orphan Drug Designation Granted by U.S. FDA for Anal Cancer

Invion Limited (IVX:AU) has announced Orphan Drug Designation Granted by U.S. FDA For Anal CancerDownload the PDF here. Keep Reading...
Trading Halt

Trading Halt

Invion Limited (IVX:AU) has announced Trading HaltDownload the PDF here. Keep Reading...

Latest Press Releases

Related News